CHRS vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

CHRS

42.9
AI Score
VS
CHRS Wins

CBIO

41.1
AI Score

Investment Advisor Scores

CHRS

43score
Recommendation
HOLD

CBIO

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CHRS CBIO Winner
Revenue 1.40M 1.04M CHRS
Net Income -55.34M -48.12M CBIO
Net Margin -3966.7% -4631.4% CHRS
Operating Income -129.06M -51.09M CBIO
ROE -172.2% -29.5% CBIO
ROA -32.1% -26.3% CBIO
Total Assets 172.25M 182.76M CBIO
Cash 73.35M 171.59M CBIO
Current Ratio 4.27 9.66 CBIO
Free Cash Flow -131.50M -28.56M CBIO

Relative Price Performance (Last 90 Days)

CHRS 1M: -47.4% · 3M: -53.9% CBIO 1M: +17.0% · 3M: -14.1%

Current Technical Phase

CHRS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -14.0%), weak momentum, RSI 29

RSI (14): 29.3 · Price: $0.55

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 57.3 · Price: $14.72

Fundamentals Snapshot

Metric CHRS CBIO
Market Cap — —
Forward P/E -0.9 -5.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.2% 0.0%
Gross Margin 0.7% 1.0%
Operating Margin -2.4% -14.3%
EPS -1.12 -7.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CHRS is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.